UroGen Pharma Stock Price

-0.33 (-2.13%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
UroGen Pharma Ltd URGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.33 -2.13% 15.16 00:00:06
Open Price Low Price High Price Close Price Prev Close
15.48 15.20 15.9478 15.50 15.49
Bid Price Ask Price Spread News
14.97 46.91 31.94 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,288 237,961 $ 15.48 $ 3,683,817 - 14.61 - 28.20
Last Trade Time Type Quantity Stock Price Currency
16:30:36 formt 100 $ 15.16 USD


Draw Mode:

UroGen Pharma Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 338.05M 22.30M 17.36M $ 11.80M $ - -5.92 -2.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 97.82k 2.60%

more financials information »

UroGen Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical URGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week16.0016.0115.0615.3691,944-0.84-5.25%
1 Month15.7116.1814.6115.37167,048-0.55-3.5%
3 Months18.6219.185414.6116.38146,976-3.46-18.58%
6 Months22.0628.2014.6118.82166,472-6.90-31.28%
1 Year22.9128.2014.6119.98164,510-7.75-33.83%
3 Years45.4655.491.0027.81165,571-30.30-66.65%
5 Years13.2869.56761.0030.88147,2551.8814.16%

UroGen Pharma Description

UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. It has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. The company's lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.

Your Recent History
UroGen Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.